Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.47 |
| ▸ | F10 | P00742 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033203 | 0.90 | NPY5R (0.49) | NPY5RF10SMN1; SMN2LMNATSHR | |
| SCHEMBL3033201 | 0.90 | NPY5R (0.49) | NPY5RF10SMN1; SMN2LMNATSHR | |
| SCHEMBL13290734 | 0.90 | NPY5R (0.50) | NPY5RF10SMN1; SMN2LMNATSHR | |
| SCHEMBL2942799 | 0.90 | F10 (0.41) | NPY5RF10SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL2942800 | 0.90 | F10 (0.41) | NPY5RF10SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL13290759 | 0.90 | NPY5R (0.49) | NPY5RF10SMN1; SMN2LMNATSHR | |
| SCHEMBL2944263 | 0.89 | F10 (0.42) | F10SMN1; SMN2LMNATSHRMAPK1 | |
| SCHEMBL2944267 | 0.89 | F10 (0.42) | F10SMN1; SMN2LMNATSHRMAPK1 | |
| SCHEMBL13290884 | 0.88 | NPY5R (0.47) | NPY5RF10SMN1; SMN2LMNATSHR | |
| SCHEMBL13290745 | 0.88 | NPY5R (0.48) | NPY5RF10SMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | NPY5R 805/4885F10 4/4885SMN1; SMN2 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.